Skip to main content

Table 1 Utility and cost values, base case analysis

From: Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

Utilities
State Mean (SD) Source
Pettersson score 0–4 0.82 (± 0.13) Fischer, K. et al.[6]
Pettersson score 5–12 0.81 (± 0.12)
Pettersson score 13–21 0.77 (± 0.13)
Pettersson score 22–39 0.74 (± 0.12)
Pettersson score 40–78 0.72 (± 0.11)
Orthopaedic surgery -0.39 (± 0.04) Ballal, R. D. et al.[19] Utility decrement is assumed to last for 30.4 days. Standard deviation not reported, 10% assumed
Hospitalisation due to major bleed -0.39 (± 0.04) Assumption. Utility decrement is assumed to be the same as for orthopaedic surgery but for a shorter time period (3.6 days)
Costs
Input Mean (CNY) Source
BAY 81–8973 per IU 4.488 Huo et al.[20]
rAHF-PFMper IU 4.488 Huo et al.[20]
Hospitalization for major bleed 74,122 Expert opinion, based on survey
Physician visit 500 Expert opinion, based on survey
Cost of orthopaedic surgery 300,465 Expert opinion, based on survey
Rehabilitation costs 937.50 Expert opinion, based on survey
Total compensation per hour 25.40 National Bureau of Statistics of China[21]
Resource Use
Input Unit/Frequency Source
Extra dose for treatment of bleed – BAY 81–8973 24.11 IU/kg Calculated
Extra dose for treatment of bleed – rAHF-PFM 24.55 IU/kg Calculated
Doctor visits (with or without joint bleeds) 12 / year Expert opinion
Retirement age 60 China labour statistics[22]
Full time employment 45.6% Sun et al.[23]
Missing days of work, annual 3.40 Chen et al. 2017[24]
  1. rAHF-PFM: antihemophilic factor (recombinant) plasma/albumin-free method